For a patient on buspirone 10 mg three times daily who denies jitteriness but reports worsening dyspnea (air hunger) over the past two days after initially feeling fine, should the current dose be continued and what adjunctive measures are appropriate?

Worsening Air Hunger on Buspirone: Immediate Evaluation and Management

The worsening dyspnea (air hunger) after initial improvement on buspirone 10 mg TID requires immediate medical evaluation to rule out serious causes before attributing symptoms to anxiety, as air hunger is a primal homeostatic alarm signal that may indicate respiratory, cardiovascular, or metabolic decompensation rather than anxiety alone.

Critical First Step: Rule Out Medical Causes

Air hunger is fundamentally different from anxiety-related breathlessness. It represents a primal sensation alerting to failure of gas exchange homeostasis 1. The American Thoracic Society emphasizes that dyspnea is a subjective perception that can only be assessed through self-report, and it must be distinguished from anxiety 2. The sudden worsening after initial stability is a red flag.

Immediate Assessment Required:

• Pulse oximetry and arterial blood gas - Check for hypoxemia, hypercapnia, or acidosis (all potent triggers of air hunger) 1
• Cardiac evaluation - Rule out acute coronary syndrome, heart failure, or arrhythmia
• Pulmonary examination - Assess for pneumonia, pneumothorax, pulmonary embolism, or COPD exacerbation
• Metabolic panel - Check for metabolic acidosis

Buspirone's Paradoxical Effects on Respiration

Buspirone actually stimulates respiration rather than suppressing it 3. In animal studies, buspirone increased respiratory output and shifted the apneic threshold to lower CO2 levels - the opposite of sedating anxiolytics 3. However, this respiratory stimulation may paradoxically worsen the sensation of air hunger in some patients.

Key Pharmacological Considerations:

Buspirone has stimulant rather than sedative properties 4. Studies show it can:

• Increase wake time after sleep onset 4
• Cause activation as an adverse effect 5
• Potentially worsen anxiety symptoms in some patients 6

The FDA label does not list dyspnea as a common adverse effect 7, but recent pharmacovigilance data from 2006-2025 identified anxiety (n=133) and drug interactions (n=86) as frequent adverse events 6.

Clinical Decision Algorithm

If Medical Causes Are Ruled Out:

Option 1: Discontinue Buspirone (Recommended)

• The worsening after initial improvement suggests the drug may be contributing to symptoms
• Buspirone's stimulant properties may be exacerbating the sensation of air hunger
• No withdrawal syndrome occurs with abrupt discontinuation 4

Option 2: Reduce Dose (Alternative)

• If partial benefit was achieved, consider reducing to 5 mg TID
• Monitor closely for 48-72 hours
• The FDA label supports dose adjustments based on clinical assessment 7

If Medical Causes Are Present:

Do not continue current buspirone dose. Palliative care guidelines emphasize that dyspnea requires opioids (not buspirone) for symptom relief 8. Opioids reduce dyspnea; benzodiazepines reduce associated anxiety 8.

Evidence on Buspirone for Dyspnea

While one 1993 study showed buspirone improved breathlessness in COPD patients 9, this was in the context of chronic lung disease with baseline anxiety - not acute worsening of air hunger in a patient on stable therapy. That study's context does not apply to your patient's acute deterioration.

Critical Pitfalls to Avoid

1. Do not assume worsening dyspnea is "just anxiety" - Air hunger activates the insular cortex and limbic structures similarly to pain 1, and represents a genuine homeostatic threat signal 2

2. Do not increase buspirone dose - The stimulant properties may worsen symptoms 4

3. Do not add benzodiazepines without medical clearance - While benzodiazepines reduce anxiety-related dyspnea 8, they should not be used until serious medical causes are excluded

4. Watch for drug interactions - Buspirone has significant CYP3A4 interactions that can increase plasma concentrations 4-20 fold 7

Recommended Action Plan

Discontinue buspirone immediately and obtain urgent medical evaluation including pulse oximetry, physical examination for respiratory distress signs, and consideration of chest imaging and cardiac workup. If medical causes are identified, treat the underlying condition with appropriate therapies (opioids for dyspnea relief if indicated per palliative guidelines 8). If evaluation is negative and symptoms resolve off buspirone, consider alternative anxiolytics without stimulant properties. The patient's initial improvement followed by deterioration suggests the drug is not providing sustained benefit and may be contributing to the problem.